Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | TNK2 | Q07912 | 3/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.36 |
| ▸ | DHFR | P00374 | 1/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.35 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.34 |
| ▸ | ACP1 | P24666 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | NPY1R | P25929 | 1/20 | 0.33 |
| ▸ | NPY2R | P49146 | 1/20 | 0.33 |
| ▸ | NPY4R | P50391 | 1/20 | 0.33 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21903461 | 0.87 | DHFR (0.40) | MEN1KMT2ATNK2DHFRHSD11B1 | |
| SCHEMBL31204206 | 0.87 | DHFR (0.40) | MEN1KMT2ATNK2DHFRHSD11B1 | |
| SCHEMBL3500438 | 0.86 | TNK2 (0.44) | MEN1KMT2ATNK2HRH3DHFR | |
| SCHEMBL15584178 | 0.84 | DHFR (0.36) | MEN1KMT2ATNK2DHFRHSD11B1 | |
| SCHEMBL3143065 | 0.84 | HRH3 (0.52) | MEN1KMT2ATNK2HRH3NPC1 | |
| SCHEMBL8434147 | 0.81 | TNK2 (0.40) | MEN1KMT2ATNK2HRH3DHFR | |
| SCHEMBL25266004 | 0.81 | RAB9A (0.45) | MEN1KMT2AHRH3NPC1RAB9A | |
| SCHEMBL25190658 | 0.81 | RAB9A (0.45) | MEN1KMT2AHRH3NPC1RAB9A | |
| SCHEMBL20570060 | 0.81 | MEN1 (0.56) | MEN1KMT2AHRH3KDM4CNPC1 | |
| SCHEMBL7362854 | 0.81 | HRH3 (0.42) | MEN1KMT2ATNK2HRH3DHFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104119285-B | Compound and application thereof as estrogen-related receptor modulator | 中国科学院广州生物医药与健康研究院 | 2016-06-29 | — | — | CN | disclosed |
| CN-104119285-A | Compound used as estrogen-related receptor regulator and application of compound | GUANGZHOU INST BIOMED & HEALTH | 2014-10-29 | — | — | CN | disclosed |
| US-8716355-B2 | Hydroxylated tolans and related compounds in the treatment of a cancer | KENT STATE UNIVERSITY (US) | 2014-05-06 | — | — | US | disclosed |
| US-8716355-B2 | Hydroxylated tolans and related compounds in the treatment of a cancer | KENT STATE UNIVERSITY (US) | 2014-05-06 | — | — | US | disclosed |
| US-8716355-B2 | Hydroxylated tolans and related compounds in the treatment of a cancer | KENT STATE UNIVERSITY (US) | 2014-05-06 | — | — | US | disclosed |
| US-8680142-B2 | Ascorbate, vitamin K3 and hydroxytolans in the treatment of cancer | KENT STATE UNIVERSITY (US) | 2014-03-25 | — | — | US | disclosed |
| US-8680142-B2 | Ascorbate, vitamin K3 and hydroxytolans in the treatment of cancer | KENT STATE UNIVERSITY (US) | 2014-03-25 | — | — | US | disclosed |
| US-8680142-B2 | Ascorbate, vitamin K3 and hydroxytolans in the treatment of cancer | KENT STATE UNIVERSITY (US) | 2014-03-25 | — | — | US | disclosed |
| EP-1731587-B1 | Process for the preparation of tolanes | MERCK PATENT GMBH (DE) | 2013-01-23 | — | — | EP | disclosed |
| US-20110160301-A1 | ASCORBATE, VITAMIN K3 AND HYDROXYTOLANS IN THE TREATMENT OF CANCER | KENT STATE UNIVERSITY (US) | 2011-06-30 | — | — | US | disclosed |
| WO-2008157745-A1 | ASCORBATE, VITAMIN K3 AND HYDROXYTOLANS IN THE TREATMENT OF CANCER | KENT STATE UNIVERSITY (US) | 2008-12-24 | — | — | WO | disclosed |
| WO-2008157787-A2 | HYDROXYLATED TOLANS AND RELATED COMPOUNDS IN THE TREATMENT OF CANCER | KENT STATE UNIVERSITY (US) | 2008-12-24 | — | — | WO | disclosed |
| US-7094809-B2 | Topical administration of dihydroxytoluene to block viral replication | NORTHEASTERN OHIO UNIVERSITIES COLLEGE OF MEDICINE (US) | 2006-08-22 | — | — | US | disclosed |
| US-6805920-B2 | For producing liquid crystal display (LCD) | NITTO DENKO CORPORATION (JP) | 2004-10-19 | — | — | US | disclosed |
| US-20030203974-A1 | Methods for treating subjects infected with herpes virus or Neisseria gonorrheae | DOCHERTY JOHN (US) | 2003-10-30 | — | — | US | disclosed |
| US-6599945-B2 | Administering a hydroxylated tolan to the host cell of a patient having or suspected having an infection induced by herpes virus | NORTHEASTERN OHIO UNIVERSITIES COLLEGE OF MEDICINE | 2003-07-29 | — | — | US | disclosed |
| EP-1311254-A2 | METHODS FOR TREATING SUBJECTS INFECTED WITH A HERPES VIRUS OR i NEISSERIA GONORRHEAE /i | Northeastern Ohio Universities (US) | 2003-05-21 | — | — | EP | disclosed |
| US-20030072893-A1 | Polymerizable liquid crystal compound and optical film | NITTO DENKO CORPORATION (JP) | 2003-04-17 | — | — | US | disclosed |
| US-20020103262-A1 | Methods for treating subjects infected with a herpes virus or neisseria gonorrheae | KENT STATE UNIVERSITY | 2002-08-01 | — | — | US | disclosed |
| WO-2002013764-A2 | METHODS FOR TREATING SUBJECTS INFECTED WITH A HERPES VIRUS OR NEISSERIA GONORRHEAE | NORTHEASTERN OHIO UNIVERSITIES COLLEGE OF MEDICINE (US) | 2002-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110160301-A1 | ASCORBATE, VITAMIN K3 AND HYDROXYTOLANS IN THE TREATMENT OF CANCER | PROC, VKORC1L1, VKORC1 | MEN1 1468/4885KMT2A 1792/4885TNK2 2129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.